323 related articles for article (PubMed ID: 1312718)
1. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
Yano T; Pinski J; Radulovic S; Schally AV
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone.
Sharoni Y; Bosin E; Miinster A; Levy J; Schally AV
Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1648-51. PubMed ID: 2646641
[TBL] [Abstract][Full Text] [Related]
4. Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors.
Hershkovitz E; Marbach M; Bosin E; Levy J; Roberts CT; LeRoith D; Schally AV; Sharoni Y
J Clin Endocrinol Metab; 1993 Oct; 77(4):963-8. PubMed ID: 8408472
[TBL] [Abstract][Full Text] [Related]
5. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
Milovanovic SR; Radulovic S; Schally AV
Breast Cancer Res Treat; 1992; 24(2):147-58. PubMed ID: 8443402
[TBL] [Abstract][Full Text] [Related]
7. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV
Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
Yano T; Korkut E; Pinski J; Szepeshazi K; Milovanovic S; Groot K; Clarke R; Comaru-Schally AM; Schally AV
Breast Cancer Res Treat; 1992; 21(1):35-45. PubMed ID: 1391973
[TBL] [Abstract][Full Text] [Related]
11. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.
Reissmann T; Hilgard P; Harleman JH; Engel J; Comaru-Schally AM; Schally AV
J Cancer Res Clin Oncol; 1992; 118(1):44-9. PubMed ID: 1530849
[TBL] [Abstract][Full Text] [Related]
12. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
[TBL] [Abstract][Full Text] [Related]
13. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
Srkalovic G; Wittliff JL; Schally AV
Cancer Res; 1990 Mar; 50(6):1841-6. PubMed ID: 2155060
[TBL] [Abstract][Full Text] [Related]
14. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.
Srkalovic G; Bokser L; Radulovic S; Korkut E; Schally AV
Endocrinology; 1990 Dec; 127(6):3052-60. PubMed ID: 2174343
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
Halmos G; Schally AV; Kahan Z
Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
[TBL] [Abstract][Full Text] [Related]
16. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.
Janáky T; Juhász A; Bajusz S; Csernus V; Srkalovic G; Bokser L; Milovanovic S; Redding TW; Rékási Z; Nagy A
Proc Natl Acad Sci U S A; 1992 Feb; 89(3):972-6. PubMed ID: 1310542
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
J Natl Cancer Inst; 1990 Mar; 82(6):513-7. PubMed ID: 2156080
[TBL] [Abstract][Full Text] [Related]
20. Similar luteinizing hormone-releasing hormone binding sites in rat anterior pituitary and ovary.
Reeves JJ; Séguin C; Lefebvre FA; Kelly PA; Labrie F
Proc Natl Acad Sci U S A; 1980 Sep; 77(9):5567-71. PubMed ID: 6254091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
